Tandem Diabetes Care, Inc.
https://www.tandemdiabetes.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tandem Diabetes Care, Inc.
FDA Officially Designates Tandem’s Control-IQ Class II
After more than three years of treating the Tandem Diabetes Care Control-IQ Technology system as moderate-risk class II, the US FDA has made the designation official. The classification will also apply to future similar devices.
Exec Chat: Dexcom’s CEO Bullish On Year Ahead With G7 CGM Launch, Dexcom One CGM Expansion
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.
Dexcom Announces CGM Real-Time Data Now Available On Garmin Wearables, Bike Computers
Dexcom is making CGM data available through consumer devices starting with Garmin’s smartwatches and bicycle computers.
Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Monitoring Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
In Vitro Diagnostics
- Glucose Testing